by Annabel Sedgwick
Share
by Annabel Sedgwick
Share
UK-based regulatory consultancy company Mosaic Surgical has formed a partnership with Key2Compliance – a Swedish provider of customised business solutions in the life sciences arena – to overcome some of the challenges associated with the UK leaving the European Union. From May 2021, medical device manufacturers outside of the UK wishing to sell their products into this market must do so with the representation of an appointed UK Responsible Person.
Key2Compliance offers a full suite of services – including quality assurance, training and regulatory affairs – and, with Mosaic Surgical acting as its UK Responsible Person, the company can provide a one-stop shop to ensure uninterrupted trade with the UK. Jan Hellqvist, CEO of Key2Compliance, stated: “A number of our clients wish to continue to sell their products in the UK, so we are excited to support them through this transition, thanks to our partnership with Mosaic Surgical. Formation of this collaboration has been friction-free, which is exactly what we want for our customers, and we are pleased to recommend Mosaic Surgical as a UK Responsible Person.”
Heather Pendlebury, QARA Manager at Mosaic Surgical, said: “It’s extremely important to find someone in the UK that you can trust will act as a reliable representative following Brexit. We are delighted to be working with Key2Compliance, and have formed a very positive working relationship, which will help to make this process as smooth as possible for non-UK manufacturers.”
To read more about Mosaic Surgical, visit www.mosaicsurgical.com
To learn more about Key2Compliance, visit www.key2compliance.com
About Mosaic Surgical Ltd
Mosaic Surgical Ltd is the manufacturing arm of a group of trusted medical devices companies. It has brought many successful solutions to market that solve immediate clinical needs, including flagship products such as the Galaxy II™ retractor and newly launched eVeck™ colposcopy kit.
Microban® International – the global leader in antimicrobial additives and odor control solutions – has released a statement discrediting unwarranted claims about the safety and efficacy of antimicrobial technologies. This statement is intended to ensure that the public, consumers, and other stakeholders are equipped to make fully informed decisions, based on scientific reasoning. Making a clear distinction between public health and non-public health claims, Microban has explained the advantages of incorporating its antimicrobial additives into
Anion dysregulation is seen in numerous diseases, from cystic fibrosis and chronic pain, to autism and cancer. Researchers at the University of Dallas are investigating anion transport in vivo, developing novel tools to help analyze the effects of both normal and aberrant anion regulation at the molecular level, and are using INTEGRA’s PIPETBOY acu 2 to streamline their cell
June Medical is one of 48 organisations to be recognised for their excellence in innovation in this year’s Queen’s Awards for Enterprise. Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country – rewarding only the most outstanding achievements – with winning businesses able to use the esteemed
A report from the International Agency for Research on Cancer1 recently classified TiO2 as ‘possibly carcinogenic to humans’ by inhalation and similarly, the European Chemicals Agency2 recommended TiO2 be classified as a category 2 carcinogen (suspected of causing cancer). In contrast, antimicrobial technologies from Microban International are based on SilverShield®, the first patented antimicrobial solution